PET/CT: C-reactive protein could be a precursor to cardiovascular disease

FDG uptake rose substantially in PET/CT scans of patients with higher levels of C-reative protein in their carotid arteries, pinpointing a potential biomarker for cardiovascular disease, according to an article published online Oct. 31 in the Journal of Nuclear Medicine.

Tae Soo Noh, a researcher from the department of nuclear medicine at Samsung Medical Center and Sungkyunkwan University School of Medicine in Seoul, Korea, and colleagues assessed the association between F-18 FDG uptake in carotid arteries, a

high-sensitivity C-reactive protein and patient risk using the standard Framingham risk score (FRS), which calculated the estimated 10-year risk of developing cardiovascular disease in a group of 1,181 adults without symptoms of heart disease.

“High carotid F-18 FDG uptake in asymptomatic adults is associated with increased clinical risk factors and greater FRS,” wrote the authors. “Furthermore, carotid F-18 FDG uptake appears to reflect aspects of atherosclerotic inflammation distinct from [high-sensitivity C-reactive protein] level and may offer incremental risk–related information.”

Researchers found that FRS scores swelled from about 11.5 percent risk of developing cardiovascular disease to 14.8 percent in patients with maximum target-to-background ratios greater or equal to 1.7, indicating a strong link between FDG uptake, carotid C-reative protein levels and risk of disease.

Additional studies need to be conducted to gain a better understanding of the full impact of C-reative protein levels in the development of atherosclerosis.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.